Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05853718
PHASE4
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
Sponsor: First People's Hospital of Hangzhou
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
Official title: Study to Evaluate the Pharmacokinetic, Safety, and Efficacy of TAF in HBV-Infected Pregnant Women
Key Details
Gender
FEMALE
Age Range
20 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2021-05-06
Completion Date
2025-12-30
Last Updated
2025-09-08
Healthy Volunteers
No
Interventions
DRUG
Tenofovir Alafenamide Tablets
Take 25mg TAF daily from week 28-32 of gestation until delivery
Locations (1)
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China